CSL Behring files for MAA of haemophilia B gene therapyCSL Behring has filed for accelerated approval of the first hemophilia B gene therapy in Europe. more ➔
Argenx SE to raise €637mDutch autoimmunity specialist Argenx SE has raised $700m to prepare commercialisation of subcutanous efgartigimod as treatment for generalized myasthenia gravis. more ➔
Bayer invests into synthetic TCRs for cell therapyTCR-T cell therapy specialist Affini-T Therapeutics Inc. (Seattle, Boston) has raised $175m Series A fnancing co-Led by Vida Ventures and Leaps by Bayer more ➔
Bavarian Nordic bags $225m for licence to RSV vaccineBavarian Nordic is to receive up to US$225 and double-digit royalties for granting exclusive Chinese commercialisation rights for MVA-BN® RSV to Nuance Pharma. more ➔
Switzerland paves the way for genome editingSwitzerland is keeping its moratorium on GMO cultivation until 2025, but paving the way for exceptions in precision breeding. more ➔
Gilde Healthcare Private Equity IV launches €517mGilde Healthcare Private Equity IV (GHPE IV) has closed at €517m for investments in proifitable healthcare companies in the lower mid-market in North-west Europe. more ➔
Precirix NV raises €80m in Series B financingWith €80m from a Series B financing in its pocket, Belgian Precirix NV plans to advance its pipeline of precision radiopharmaceuticals. more ➔
Sanofi bags €300m from US investor BlackstoneSanofi has secured money from Blackstone Life Sciences to speed up development of its daratumumab competitor isatuximab in multiple myeloma. more ➔
Join 900 US CEOs protest against Ukraine invasion US Life Science leaders pledge to economically disengage from Russia. more ➔
Scenic Biotech BV announces $31m financingScenic Biotech BV will use an incoming $31m (€28) Series A financing to advance its pipeline of genetic modifiers, a new molecular entity in cancer and rare disease. more ➔ · & … more ➔
